It is 25 years since Dame Cicely Saunders set up St Christopher's Hospice, and since then the palliative care movement has found world-wide expression through inpatient facilities, linked home care schemes and a growing acceptance of symptom control and whole-person care in mainstream medicine. At this point people are naturally asking what we can expect, or what should we seek to do, in the next 25 years.
What we have come to mean by hospice care is now a cluster of understood principles and practices, varying from one country to another according to conditions and resources: there will be other variationsnot least in the balance of the public and voluntary sectors. But the biggest predictable change is the matter of scale. In the cancer field alone, where palliative care was established and most of its effort is found, demographic and health statistics point to a sustained increase in the number of people with cancer. Within the next quarter of a century, for instance, malignant neoplasms in the UK will rise by at least 50%, and the prospect is similar in other developed countries. This alone raises policy and resource issues. In Britain it could mean that the hospice movement would need to make a comparable expansion merely to maintain its present positionmore beds, more staff, more volunteers, more money. Anyone who is familiar with the task of meeting present commitments will immediately realize how much more will be asked cf the hospice movement in the years ahead. It may, in fact, prove difficult merely to sustain the present 'hospice' proportion of total care for patients with cancer. The share of the voluntary sector could well fall even though overall numbers increase. This is a sobering thought, and it has already made people speculate about the future relationship of the public and private sectors of cancer care -speculation that has recently been enhanced in the United States by controversies about Medicare and in Britain by the complex and unresolved changes in the National Health Service. Does one see a future in which independent hospices increasingly become providers of specified and publicly funded services, their present fund-raisers and their volunteers reverting to a more traditional and diminished role as auxiliaries to public (or even profit-making) institutions? How far would such a process go before there were serious doubts about independence? Would there be a gradual standardization (or a fall in standards) as the rules of funding were used to establish policy and performance criteria common to both public and voluntary care facilities? And if such changes occur, how can the hospice movement go on playing the complementary and innovative role which it has performed so well during the past two decades?
The time has surely come to begin an informed debate on these issues, a debate which should be promoted and focused by professional organizations and, where there are such bodies as the newly established National Hospice Council, by those who speak for the whole palliative care constituency. One can easily identify some of the fundamental questions that should be asked, some of them urgent because we do not really know the answers and they may well be posed in the near future by policymakers wondering how best to provide care for the sick in an ageing population. They are quantifiable questions about numbers, costs, the balance of work between inpatient and home care, the contribution of the lengthening train of supporting professionals; and they are also questions about purpose and quality, about the differences between palliative and mainstream terminal care, and about the ease or difficulty of transferring experience from one sector to the other. So far, there has been a good deal more anecdotal than operational research about palliative care, and there is no doubt that one of the coming changes will be pressure to firm up the evidence which we believe is there but cannot yet provide. This debate, moreover, will be taking place in a much colder economic climate than the last two decades, at a time when general concern about public expenditure confronts the specific threat of an ageing population -in the US, for example, a presidential commission suggests that within 10 years health care costs will absorb onethird of the GNP. It has so far been possible to insulate cancer care from the wider problem of the aged and infirm because it has definable boundaries, and resources can therefore be targeted on it. It is a much feared scourge, so common that all families encounter it and have to provide care and support for its victims. The later stages have a fairly predictable prognosis, which helps resource planning; it is amenable to significant pain control; and it raises problems about dying and death that can be mediated by whole-person and family support. Such distinctiveness has been accompanied by a positive reworking of the clinical and human approach to terminal illness, by the remarkable appeal of the cancer research and support charities, and by the growth of public knowledge and respect for hospice work to the point where it sets the standard of what the public expects for the last phase of life. That very success in changing attitudes to cancer and its treatment is understandably raising other questions. People who do not perceive these particular features of cancer are bound to ask why it is different, why special and often generous support should be given to cancer care that is not available to anything like the same extent for those suffering from other life-disabling and life-threatening illnessnotably Alzheimer and Parkinson patients, but extending to cardiac and respiratory conditions, strokes and advanced arthritis. Why not include them in the ambit of hospice and home care support?
There are two simple answers to that simple and well-intentioned question. The first is the difficulty of predicting the duration of a terminal phase in such illnesses; and the period of incapacity may be long, drawn-out and drain energies and resources indefinitely. The second is the sheer scale of need, real human need, which far exceeds the claims of cancer patients and will inevitably impose great strains on whatever systems of community care for the aged we can put in place in the coming years. The effort must of course be made, because the problem of degenerative states among the elderly is already beginning to swamp primary care teams and hospital facilities, imposing great strains on family carers, on friends and on neighbours. Quantitatively it is a far greater problem than cancer and the conditions of modern life exacerbate it. Families are smaller, children move away, more women are employed full or parttime, and younger people have come to expect the state to assume much of the burden of caring. In Britain, for example, we are looking at a population where already two-thirds of all women over 75 live alone, and where it is estimated that something like 2.5 million carers over pensionable age are caring for someone older and sicker than themselves. There are certainly lessons to be learned from hospice care, both in attitudes and practices, and especially in the organization of home support services. But it is unlikely that the palliative care movement, facing its own mountain of demographic obligation, can offer much direct help.
Of course, a number of hospices already admit a small number of patients with conditions other than cancer, such as motor neurone disease, which have a broadly comparable course and can be accommodated in much the same framework of care. Even more might do so if they did not feel themselves morally or legally confined to cancer care. But all this is at the margin. The only significant disease that is generating real numbers of claimants for hospice care is AIDS. It is such an obvious candidate that the founding of special hospices was one of the immediate responses: it is an illness that evokes as much dread as cancer, and generates as much caring support; it has a high and early mortality rate, and threatens to proliferate widely before effective treatments are developed. If there is ever to be a case for extending the scope of hospice work from its primary concern with cancer, it is the self-evident case for AIDS. All the problems involved seem to be manageable, though some are tricky, and the numbers coming forward are likely to be manageable too (though in some parts of the world AIDS victims will rightly be given the kind of priority that has characterized cancer care in developed countries). A significant extension of palliative care for AIDS patients may, indeed, be the only major diversification that can reasonably be assimilated by the hospice movement as it stands today. The limited number of patients with AIDS already under hospice care are surely harbingers of the larger and carefully reported pilot schemes which are needed in Britain, though there is already significant experience elsewhere.
There is a further argument for pilot schemes of diversification and for encouraging a more active evaluation of all aspects of the hospice movement, particularly co-ordination of the community services. If the direct help it can give to the elderly with degenerative disease is unavoidably limited it can, nonetheless, make a significant indirect contribution. Its 25 year experience certainly shows how medical and public attitudes to a dreaded condition can be changed, how means can be found to control and relieve symptoms, how support services can be offered to patients and carers, how funds can be raised and volunteers mobilized. It is full of examples which can suggest new ways of helping tens of thousands who suffer from the life disabling conditions of old age, whether they subsist in geriatric wards, or residential homes, or struggle on in their own homes, sapping the strength of those who care as best they can. The actual challenge of this pool of human misery among the old is being faced by others, resolute and hard-pressed. But much more will have to be done in reorganized systems of community care, and there is an example to encourage them. The hospice movement sprang from a wonderfully committed belief that the last phase of life for a cancer patient should be eased, enhanced and made as dignified as possible, and that the lives and feelings of the carers also mattered. Though such a quality cannot be quantified there is no doubt that it can be communicated.
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